Bora CDMO Bora CDMO

X

Find Drugs in Development News & Deals for Marstacimab

PharmaCompass
API SUPPLIERS
API Suppliers

API Suppliers

0

US DMFs Filed

US DMFs Filed

0

CEP/COS Certifications

CEP/COS Certifications

0

JDMFs Filed

JDMFs Filed

0

Other Certificates

Other Certificates

0

Other Suppliers

Other Suppliers

0

API REF. PRICE (USD / KG)

0

INTERMEDIATES

0

DOSSIERS // FDF
USA (Orange Book)

USA (Orange Book)

0

Europe

Europe

0

Canada

Canada

0

Australia

Australia

0

South Africa

South Africa

0

Uploaded Dossiers

Uploaded Dossiers

0

GLOBAL SALES (USD Million)

U.S. Medicaid

0

Annual Reports

0

EXCIPIENTS

0

PATENTS & EXCLUSIVITIES

USFDA Orange Book Patents

0

USFDA Exclusivities

0

DIGITAL CONTENT

Blog #PharmaFlow

0

News

REF STANDARD

EDQM

0

USP

0

JP

0

Other Listed Suppliers

0

SERVICES

0

Details:

PF-06741086 (marstacimab) is a human monoclonal immunoglobulin G isotype, subclass 1 (IgG1) that targets the TFPI and development as a prophylactic and subcutaneous treatment for severe hemophilia A or moderately severe to severe hemophilia B with or without inhibitors.


Lead Product(s): Marstacimab

Therapeutic Area: Genetic Disease Product Name: PF-06741086

Highest Development Status: Phase IIIProduct Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable December 11, 2023

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

PF-06741086 (marstacimab) is a human monoclonal immunoglobulin G isotype, subclass 1 (IgG1) that targets the TFPI and development as a prophylactic and subcutaneous treatment for severe hemophilia A or moderately severe to severe hemophilia B with or without inhibitors.


Lead Product(s): Marstacimab

Therapeutic Area: Genetic Disease Product Name: PF-06741086

Highest Development Status: Phase IIIProduct Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable May 30, 2023

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

The completed Phase 2 study results demonstrated that treatment with marstacimab resulted in significant (>75%) reductions in ABR for all participants in the study population.


Lead Product(s): Marstacimab

Therapeutic Area: Genetic Disease Product Name: PF-06741086

Highest Development Status: Phase IIIProduct Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable November 23, 2020

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty
Post Enquiry
POST ENQUIRY